Member Info for mol42

Updated for our new Finance Director

https://optibiotix.com/corporate/

good photo

hope he lasts longer than Graham Myers

and pity the rest of the website didn't have a makeover - now getting extremely embarrassing

mol

Https://www.scientific-exchange.com/content/dam/medical/scientific-exchange/ta/obesity/pharmacotherapies/resource-documents/wegovy-step-1-clinical-trail.pdf

https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.14725

mol

Just doodling and found wellbiome for sale on their website - albeit redirected to amazon to purchase

https://www.ypc.co.uk/product/prebiotic-fibre-complex-for-gut-health-by-wellbiome-probiotic-support-digestive-wellness-immune-system-support-dietary-supplement-for-healthy-microbiome-balance-30-servings/

mind to get to the above from home page

https://www.ypc.co.uk/

takes a bit of an effort

mol

2,120 followers

c 3h ago

The new GLP-1 anti obesity drugs have been shown to often cause nasty side effects such as gut issues, nausea and muscle loss. These new drugs therefore should not be misused by consumers simply overweight looking to improve their body aesthetics.

Once of the largest clinical trials (STEP-1) showed 40% of the weight loss in patients was in fact muscle loss. In addition, within 12 months of treatment ending it showed patients on average regained 2/3rds of the weight they had lost.

For businesses in the health and wellness sector, SlimBiome® is the award winning, patented, natural and science-backed solution offering consumers a non pharmaceutical, holistic and sustainable approach to weight loss.

Developed with world leading experts in functional foods and the microbiome, SlimBiome® offers a natural, gentle solution for the management of hunger and cravings while boosting gut health and promoting long-term weight loss.

The GLP-1 drugs have brought wide media and consumer attention towards the concept of losing weight by reducing hunger and cravings. SlimBiome® can meet the needs of the non clinically obese in a healthy and sustainable way in a new paradigm for weight management.

For patients who have lost weight and finished GLP-1 treatment, SlimBiome® can also provide a natural solution to manage appetite over the 12 months post treatment period, helping prevent the rebound weight seen in the STEP-1 study.

Join our growing list of internationally acclaimed partners in meeting the growing demand for natural, effective, healthy and sustainable weight loss solutions with SlimBiome®.

mol

On Admission. 13,998,238

25 Sep 2015 (1,400,000)

24 Jun 2016 (598,924)

6 Mar 2017 (1,500,000)

23 May 2017 (1,050,000)

19 Oct 2023 (2,361,000)

01 Mar 2024 (1,375,000)

25 Jul 2024 (1,000,000)

Total Remaining 4,713,314 as at last notification 30 Jul 24 (4.81%)

mol

𝗟𝗲𝘀𝘀 𝗦𝘂𝗴𝗮𝗿, 𝗔𝗹𝗹 𝘁𝗵𝗲 𝗧𝗮𝘀𝘁𝗲! 🧋

Did you know that sugar reduction is becoming a key factor in consumer choices for flavored milk drinks? As more people embrace healthy lifestyles, the demand for delicious, reduced-sugar options is booming. No surprise that sugar-reduction claims appeal to consumers – a fact reflected in the rise of products carrying a low- or reduced-sugar claim.

How we can help:

Our broad range of differentiated enzymatic solutions and high-performance flavor solutions make it easier than ever to meet sugar reduction goals without sacrificing taste. Whether you’re developing creamy chocolate milk or fruity dairy drinks, we are here to support.

Ready to create sugar-reduced flavored milk drinks that are great tasting? Let’s talk!

https://www.linkedin.com/posts/dsm-firmenich-taste-texture-health_webringprogresstolife-sugarreduction-flavoredmilk-activity-7269328537226993664-Opao

still waiting

mol

From probably another fundraise I would suggest

£1.26m cash at June 2024 with cash outflow of £745k for 6 months to June 24 however the last raise in Mar 2024 noted

1. active account management of existing partners by co-investing in publicity, marketing, and promotions to increase sales;

2. increased presence of the Company’s stands at major exhibitions to attract new partners, particularly in the USA and India to mitigate dependency on a small number of partners;

3. investing in marketing the Company’s products to grow sales on e-commerce platforms in India, China, USA, Europe, and the Gulf States; and

4. launch its second generation SweetBiotix and MicroBiome Modulator products.

so I would suggest cash outflow higher to 31 Dec 2024 (sales of sbtx to June 24 of £89k not included in £745k) than £745k with also increased advisor costs due to pbx spat (they are reporting £116,000 extra over costs re requistioned meeting!)

mind perhaps a deal is being done to sell our pbx holding in full - just a thought - as any voting control we thought we may have had has been shown not to be - at least at requistioned meeting - however perhaps not at voting at the next pbx agm regarding re-election of directors and giving the exec director further authority to issue further shares to his mate/s - we will see - surely opti and seneca won't make the same disasterous mistake again!

though Steen's mate must be brave investor having regard to their latest results i would suggest - completely underwhelming - all Steen has done so far is increase costs and rely on Seed Health's year on year expansion to increase total revenue as reported - the other customers' revenue declining

anyway

just a few thoughts

mol

Sorry to bust your bubble Dustbin101

but Stuart didn't choose Croda - the collaboration was there before he was appointed by about 12 months from memory

mol

Https://www.confectionerynews.com/Article/2025/01/22/prebiotic-confectionery-trends-2025-functional-sweets-shaping-gut-health-and-indulgence/

https://www.confectionerynews.com/Article/2024/08/12/trends-in-prebiotics-and-probiotics-in-confectionery/

and unfortunately no mention of us

mol

A bit of info - i stumbled across this tonight - first a bit of background

http://irs.nbtrader.co.uk/ir/SkinBiotix/newsArticle.php?id=311428223056069738&ST=SBTX

https://dsw.vc/team/doug-quinn/

Doug Quinn

Partner at DSW Ventures

1mo

Great to have completed our first investment in Northern Ireland. A fab opportunity and team!

DSW Ventures

1,965 followers

1mo

We announce today that we have backed Ulster University spin-out Dia Beta Labs Ltd to fund their development of a groundbreaking treatment for obesity and type 2 diabetes. We led the round from our SEIS Fund, which was also funded by QUBIS and Innovate UK.

This investment marks a significant milestone for us – we now have portfolio companies in every GB nation – confirming our position as THE leading early-stage VC investing ONLY in the UK regions!

Dia Beta Labs' lead candidate offers the benefits of existing GLP-1 drugs like Wegovy and Ozempic, but with significantly fewer side effects and improved long-term efficacy.

Given the first generation of GLP-1s has created Europe’s biggest company in Novo Nordisk, this investment represents a massive opportunity for our investors, as well as having the potential to make a real difference in the fight against metabolic disease. Same effect, fewer side effects.

https://dsw.vc/ulster-university-spin-out-aiming-to-disrupt-multibillion-dollar-global-market-dominated-by-drugs-such-as-wegovy-and-ozempic/

https://diabetalabs.com

albeit a different approach to ours and some way to go before commercialisation

mind we have a long way to go re substantial revenue generation and to back up our Chairman's comment from 2018

Optibiotix Health PLC is a very clever business model says chairman

after a substantial investment from him

https://www.youtube.com/watch?v=8tziIRWwWwQ&t=24s

mol

Bit of info

https://apps.apple.com/in/app/lightlife/id6738279198

https://play.google.com/store/apps/details?id=com.drmorepen.lightlife&hl=en_GB

so 100+ downloads on google but not sure re apple downloads to date

however apple history re fixes since release 19 Nov 2024

1.0.5

17 Jan 2025

We’ve rolled out a release focusing on bug fixes and UI enhancements. This update improves overall stability, refines the user interface, and enhances the app’s performance for a better experience.

1.0.4

27 Dec 2024

We’ve rolled out a release focusing on bug fixes and UI enhancements. This update improves overall stability, refines the user interface, and enhances the app’s performance for a better experience.

1.0.3

10 Dec 2024

We’ve rolled out a release focusing on bug fixes and UI enhancements. This update improves overall stability, refines the user interface, and enhances the app’s performance for a better experience.

1.0.2

1 Dec 2024

We’ve rolled out a release focusing on bug fixes and UI enhancements. This update improves overall stability, refines the user interface, and enhances the app’s performance for a better experience.

1.0.1

22 Nov 2024

We’ve rolled out a release focusing on bug fixes and UI enhancements. This update improves overall stability, refines the user interface, and enhances the app’s performance for a better experience.

1.0

19 Nov 2024

Whist only researching this tonight for the first time

i'm slightly disappointed in 100+ on google to date having regard to launch exposure (at least what has been found on this bb) and target population!

anyone else who may have more knowledge of these app things on apple store have an opinion?

mol

And Kasper will also be at

I’m excited to be attending the IPA World Congress + Probiota 2025 in Copenhagen from February 5th to 7th. It’s always a great opportunity to connect with others in the probiotics field and learn about the latest research and innovations.

If you’re also attending, let me know – I would love to meet up and exchange ideas!

mol

Not forgetting our previous update

https://probiotixhealth-ir.com/news/archive/2024/081024

released purely i believe in response to requisitioned meeting

mol

And

Kasper R. Hoffensetz

Sales Manager at ProBiotix Health

2d

Excited to be part of PharmaVenue in Barcelona, where meaningful connections and innovative ideas come together. It’s inspiring to discover how strategic collaborations can shape the future of cardiometabolic health, powered by our proprietary strain, LPLDL.

Learn more: https://lnkd.in/ddaHsHcJ

wonderfully poetic from our Kasper ( appointed Sep 2024)

https://dk.linkedin.com/in/hoffensetz

but it's sales ( and cash paid to boot ) that count

mol

Oops requistioned general meeting not agm

mol

Well noted FriedmanSowell

and to put figures on TheWigster post

Year to 31 Dec 2023 signed off by Steen 28 Jun 2024 (note UK location - lol)

3. Segmental Reporting

In the opinion of the directors, the Group has one class of business, in three geographical areas being that of identifying and

developing microbial strains, compounds and formulations for use in the nutraceutical industry. The Group sells into three highly interconnected markets, all costs assets and liabilities are derived from the UK location.

Year ended 31 December 2023 £’000

UK 65

US 1,008

Rest of world 600

Total 1,673

During the reporting period one customer represented £1.0m (59.8%) of Group revenues.

so with as rnsed today

We continued to develop our relationship with SEED Health in the US, with an increase in sales volume of 56% on the prior year

we have 1.56m from seed out of a total of 1.88m 2024 turnover - as TheWigster noted other sales reversing

and cholbiomex3 hasn't been redesignated under yourbiotix rebranding on website nor does it appear - probably as i previously noted it contains red yeast rice rich in Monacolin K

An underwhelming and extremely disappointing financial update

The advisors obviously got their arm in re the opti seneca and pbx rnses and responses re agm @ £116,000 extra over

mol

Https://ppubs.uspto.gov/dirsearch-public/print/downloadBasicPdf/20250025522?requestToken=eyJzdWIiOiI3Zjk2MDkzOS0wYzcyLTQzZjMtYWZmZS1mZWE2MjMzMDMwMzAiLCJ2ZXIiOiIzMWI4OWRkYi1iMWIyLTQ1ZDctODdjMC1hNGIwZDU0NjYyMjQiLCJleHAiOjB9

Continuation of filing from 2017 and 2018 and then 2024

mol

A fuller report here

https://www.skinbiotherapeutics.com/wp-content/uploads/2024/06/SkinBiotherapeutics-Project-Mirror-Study-Report.pdf

mol

A reminder of results in powder form

https://www.londonstockexchange.com/news-article/SBTX/axisbiotix-acne-study-reports-positive-data/16523789

https://www.datitude.co.uk/client/skinbiotherapeutics-plc

mol

Just to complete the circle

https://www.amazon.in/sp?ie=UTF8&seller=A1MEZA4HWODILR&asin=B0D2DN4NVK&ref_=dp_merchant_link&isAmazonFulfilled=1

https://www.amazon.in/l/27943762031?ie=UTF8&marketplaceID=A21TJRUUN4KGV&me=A1MEZA4HWODILR

Our Indian subsidiary led by Dr Taru Jain

mol